Alloy Antibody Discovery Services is Led By a Team that has Put Hundreds of Antibodies into the Clinic
Get in Touch
Team
Errik Anderson – Founder, CEO, & Chairman
Bioengineer, entrepreneur, and investor who has founded or co-founded several venture-backed biotech companies, including Adimab, Alloy Therapeutics, Compass Therapeutics, Alector, Arsanis, and Avitide.
Piotr Bobrowicz – President & Head of R&D
Led scientific efforts across Compass Therapeutics (CSO, VP Translational Medicine); Adimab (Director of Platform Development, Director of Open Innovation); Merck (Group Leader): GlycoFi; University of Wroclaw.
Mike Schmidt – Chief Scientific Officer
Oversaw novel cytokine therapeutic development at Ankyra (CSO) and previously, led discovery and development of at Eleven Biotherapeutics and Compass.
John “Lippy” Lippincott – SVP Therapeutic Discovery Strategies
Co-founder of AlivaMab Discovery Services with over two decades of experience in the generation and characterization of antibodies from in vivo systems. Led antibody discovery efforts at Lake Pharma, Igenica, and Pfizer.
Richard Shimkets – SVP Genetics & CEO of Daedamab
(Alloy Athens)
Highly respected leader in the biotech community who brings over 23 years of experience, including serving as the President and CEO of Abeome and VP of Drug Discovery at CuraGen.
Kent Bondensgaard – VP Head of Antibody Discovery Services
Highly skilled and experienced scientific leader with 20 years of biologics discovery experience, and a strong track record of therapeutic antibody discovery, leading a variety of teams on >40 therapeutic antibody campaigns – numerous of which are currently in the clinic.
Martin Leach – Head of Informatics & COO Daedamab (Alloy Athens)
Former CIO of the Broad Institute and experienced technologist and data scientist who has catalyzed digital, data, and technology innovation as a leader at Alexion, Merck, Biogen, and CuraGen.
Scientific Advisors
Matthew DeLisa, PhD, William L. Lewis Professor of Engineering and Director of the Institute of Biotechnology at Cornell University, whose expertise spans synthetic glycobiology, immunoengineering, protein engineering and vaccine development.
Sai Reddy, PhD, Associate Professor of Systems and Synthetic Immunology at ETH Zurich, and an expert in the use of high-throughput antibody repertoire sequencing and computational biology to understand the immune response. Dr. Reddy previously co-founded deepCDR Biologics, a deep learning antibody discovery platform acquired by Alloy in December 2021.
Darrell Irvine, PhD, Professor at the MIT Koch Institute for Integrative Cancer Research, Howard Hughes Medical Institute Investigator, and a leading researcher in the use of materials science and engineering tools to develop novel technologies for drug delivery, vaccine development, and cancer immunotherapies.
Christopher Love, PhD, Professor in Chemical Engineering at the MIT Koch Institute for Integrative Cancer, and an expert in single-cell sequencing, systems immunology, next-generation protein biopharmaceuticals, and alternative host strain engineering.
Jeff Molldrem, MD, Professor and Chair of the Department of Hematopoietic Biology and Malignancy at the University of Texas MD Anderson Cancer Center whose expertise spans T cell receptors (TCRs), TCR mimics, and tumor immunology.
Randolph Noelle, PhD, Emeritus Professor of Microbiology and Immunology at Dartmouth University, and a leading researcher in the areas of regulatory T cell biology, B cell memory and plasma cell development, immune tolerance, cancer vaccines, and translational immunotherapy.
Kai Toellner, PhD, Professor of Adaptive Immunology at the University of Birmingham, and an expert in B cell differentiation, germinal centers, and the regulation of affinity maturation and immunoglobulin class switching.
Andrew Sewell, PhD, Professor at the Systems Immunity Research Institute at Cardiff University, and a world-leading expert in T cell biology research focused on understanding how T cells recognize their targets and applying these insights to create novel immunotherapies.